Zoetis Inc.
Zoetis Inc. (ZOE.DE) Stock Competitors & Peer Comparison
See (ZOE.DE) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ZOE.DE | €102.18 | +1.11% | 44.8B | 19.30 | €5.26 | +1.72% |
| MRK.DE | €109.35 | +1.63% | 47.8B | 18.32 | €6.00 | +2.00% |
| 2M7C.F | €1.53 | +5.52% | 3.6B | 18.38 | €0.08 | +2.26% |
| DMP.DE | €45.35 | +7.21% | 2.5B | 21.60 | €2.15 | +1.94% |
| EVT.DE | €4.56 | +6.32% | 792.1M | -4.95 | -€0.90 | N/A |
| 2HQ0.DE | €5.41 | -3.74% | 621M | -0.26 | -€20.54 | N/A |
| PSG.DE | €29.00 | +0.00% | 333.9M | 17.26 | €1.68 | +0.17% |
| 21P.F | €2.91 | +2.29% | 167M | -3.12 | -€0.93 | N/A |
| HAEK.DE | €21.40 | -1.83% | 111.5M | 11.57 | €1.85 | N/A |
| APPH.DE | €11.00 | +0.00% | 91.6M | 137.50 | €0.08 | N/A |
Stock Comparison
ZOE.DE vs MRK.DE Comparison April 2026
ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZOE.DE stands at 44.8B. In comparison, MRK.DE has a market cap of 47.8B. Regarding current trading prices, ZOE.DE is priced at €102.18, while MRK.DE trades at €109.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZOE.DE currently has a P/E ratio of 19.30, whereas MRK.DE's P/E ratio is 18.32. In terms of profitability, ZOE.DE's ROE is +0.58%, compared to MRK.DE's ROE of +0.09%. Regarding short-term risk, ZOE.DE is less volatile compared to MRK.DE. This indicates potentially lower risk in terms of short-term price fluctuations for ZOE.DE.Check MRK.DE's competition here
ZOE.DE vs 2M7C.F Comparison April 2026
ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZOE.DE stands at 44.8B. In comparison, 2M7C.F has a market cap of 3.6B. Regarding current trading prices, ZOE.DE is priced at €102.18, while 2M7C.F trades at €1.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZOE.DE currently has a P/E ratio of 19.30, whereas 2M7C.F's P/E ratio is 18.38. In terms of profitability, ZOE.DE's ROE is +0.58%, compared to 2M7C.F's ROE of +0.01%. Regarding short-term risk, ZOE.DE is more volatile compared to 2M7C.F. This indicates potentially higher risk in terms of short-term price fluctuations for ZOE.DE.Check 2M7C.F's competition here
ZOE.DE vs DMP.DE Comparison April 2026
ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZOE.DE stands at 44.8B. In comparison, DMP.DE has a market cap of 2.5B. Regarding current trading prices, ZOE.DE is priced at €102.18, while DMP.DE trades at €45.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZOE.DE currently has a P/E ratio of 19.30, whereas DMP.DE's P/E ratio is 21.60. In terms of profitability, ZOE.DE's ROE is +0.58%, compared to DMP.DE's ROE of +0.19%. Regarding short-term risk, ZOE.DE is less volatile compared to DMP.DE. This indicates potentially lower risk in terms of short-term price fluctuations for ZOE.DE.Check DMP.DE's competition here
ZOE.DE vs EVT.DE Comparison April 2026
ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZOE.DE stands at 44.8B. In comparison, EVT.DE has a market cap of 792.1M. Regarding current trading prices, ZOE.DE is priced at €102.18, while EVT.DE trades at €4.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZOE.DE currently has a P/E ratio of 19.30, whereas EVT.DE's P/E ratio is -4.95. In terms of profitability, ZOE.DE's ROE is +0.58%, compared to EVT.DE's ROE of -0.18%. Regarding short-term risk, ZOE.DE is less volatile compared to EVT.DE. This indicates potentially lower risk in terms of short-term price fluctuations for ZOE.DE.Check EVT.DE's competition here
ZOE.DE vs 2HQ0.DE Comparison April 2026
ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZOE.DE stands at 44.8B. In comparison, 2HQ0.DE has a market cap of 621M. Regarding current trading prices, ZOE.DE is priced at €102.18, while 2HQ0.DE trades at €5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZOE.DE currently has a P/E ratio of 19.30, whereas 2HQ0.DE's P/E ratio is -0.26. In terms of profitability, ZOE.DE's ROE is +0.58%, compared to 2HQ0.DE's ROE of -1.15%. Regarding short-term risk, ZOE.DE is less volatile compared to 2HQ0.DE. This indicates potentially lower risk in terms of short-term price fluctuations for ZOE.DE.Check 2HQ0.DE's competition here
ZOE.DE vs PSG.DE Comparison April 2026
ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZOE.DE stands at 44.8B. In comparison, PSG.DE has a market cap of 333.9M. Regarding current trading prices, ZOE.DE is priced at €102.18, while PSG.DE trades at €29.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZOE.DE currently has a P/E ratio of 19.30, whereas PSG.DE's P/E ratio is 17.26. In terms of profitability, ZOE.DE's ROE is +0.58%, compared to PSG.DE's ROE of +0.44%. Regarding short-term risk, ZOE.DE is more volatile compared to PSG.DE. This indicates potentially higher risk in terms of short-term price fluctuations for ZOE.DE.Check PSG.DE's competition here
ZOE.DE vs 21P.F Comparison April 2026
ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZOE.DE stands at 44.8B. In comparison, 21P.F has a market cap of 167M. Regarding current trading prices, ZOE.DE is priced at €102.18, while 21P.F trades at €2.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZOE.DE currently has a P/E ratio of 19.30, whereas 21P.F's P/E ratio is -3.12. In terms of profitability, ZOE.DE's ROE is +0.58%, compared to 21P.F's ROE of -0.13%. Regarding short-term risk, ZOE.DE is less volatile compared to 21P.F. This indicates potentially lower risk in terms of short-term price fluctuations for ZOE.DE.Check 21P.F's competition here
ZOE.DE vs HAEK.DE Comparison April 2026
ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZOE.DE stands at 44.8B. In comparison, HAEK.DE has a market cap of 111.5M. Regarding current trading prices, ZOE.DE is priced at €102.18, while HAEK.DE trades at €21.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZOE.DE currently has a P/E ratio of 19.30, whereas HAEK.DE's P/E ratio is 11.57. In terms of profitability, ZOE.DE's ROE is +0.58%, compared to HAEK.DE's ROE of +0.06%. Regarding short-term risk, ZOE.DE is less volatile compared to HAEK.DE. This indicates potentially lower risk in terms of short-term price fluctuations for ZOE.DE.Check HAEK.DE's competition here
ZOE.DE vs APPH.DE Comparison April 2026
ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZOE.DE stands at 44.8B. In comparison, APPH.DE has a market cap of 91.6M. Regarding current trading prices, ZOE.DE is priced at €102.18, while APPH.DE trades at €11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZOE.DE currently has a P/E ratio of 19.30, whereas APPH.DE's P/E ratio is 137.50. In terms of profitability, ZOE.DE's ROE is +0.58%, compared to APPH.DE's ROE of +0.02%. Regarding short-term risk, ZOE.DE is more volatile compared to APPH.DE. This indicates potentially higher risk in terms of short-term price fluctuations for ZOE.DE.Check APPH.DE's competition here
ZOE.DE vs 93M1.DE Comparison April 2026
ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZOE.DE stands at 44.8B. In comparison, 93M1.DE has a market cap of 82M. Regarding current trading prices, ZOE.DE is priced at €102.18, while 93M1.DE trades at €18.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZOE.DE currently has a P/E ratio of 19.30, whereas 93M1.DE's P/E ratio is -0.71. In terms of profitability, ZOE.DE's ROE is +0.58%, compared to 93M1.DE's ROE of -0.48%. Regarding short-term risk, ZOE.DE is less volatile compared to 93M1.DE. This indicates potentially lower risk in terms of short-term price fluctuations for ZOE.DE.Check 93M1.DE's competition here
ZOE.DE vs 2HQ.DE Comparison April 2026
ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZOE.DE stands at 44.8B. In comparison, 2HQ.DE has a market cap of 78.9M. Regarding current trading prices, ZOE.DE is priced at €102.18, while 2HQ.DE trades at €0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZOE.DE currently has a P/E ratio of 19.30, whereas 2HQ.DE's P/E ratio is -0.03. In terms of profitability, ZOE.DE's ROE is +0.58%, compared to 2HQ.DE's ROE of -1.15%. Regarding short-term risk, ZOE.DE is less volatile compared to 2HQ.DE. This indicates potentially lower risk in terms of short-term price fluctuations for ZOE.DE.Check 2HQ.DE's competition here
ZOE.DE vs B8F.DE Comparison April 2026
ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZOE.DE stands at 44.8B. In comparison, B8F.DE has a market cap of 20.7M. Regarding current trading prices, ZOE.DE is priced at €102.18, while B8F.DE trades at €6.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZOE.DE currently has a P/E ratio of 19.30, whereas B8F.DE's P/E ratio is -32.40. In terms of profitability, ZOE.DE's ROE is +0.58%, compared to B8F.DE's ROE of -0.02%. Regarding short-term risk, ZOE.DE is less volatile compared to B8F.DE. This indicates potentially lower risk in terms of short-term price fluctuations for ZOE.DE.Check B8F.DE's competition here
ZOE.DE vs 21P1.F Comparison April 2026
ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZOE.DE stands at 44.8B. In comparison, 21P1.F has a market cap of 19.6M. Regarding current trading prices, ZOE.DE is priced at €102.18, while 21P1.F trades at €0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZOE.DE currently has a P/E ratio of 19.30, whereas 21P1.F's P/E ratio is -0.01. In terms of profitability, ZOE.DE's ROE is +0.58%, compared to 21P1.F's ROE of -0.13%. Regarding short-term risk, ZOE.DE is less volatile compared to 21P1.F. This indicates potentially lower risk in terms of short-term price fluctuations for ZOE.DE.Check 21P1.F's competition here
ZOE.DE vs HOB0.F Comparison April 2026
ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZOE.DE stands at 44.8B. In comparison, HOB0.F has a market cap of 17M. Regarding current trading prices, ZOE.DE is priced at €102.18, while HOB0.F trades at €0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZOE.DE currently has a P/E ratio of 19.30, whereas HOB0.F's P/E ratio is 6.30. In terms of profitability, ZOE.DE's ROE is +0.58%, compared to HOB0.F's ROE of -1.18%. Regarding short-term risk, ZOE.DE is more volatile compared to HOB0.F. This indicates potentially higher risk in terms of short-term price fluctuations for ZOE.DE.Check HOB0.F's competition here
ZOE.DE vs B8FK.DE Comparison April 2026
ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZOE.DE stands at 44.8B. In comparison, B8FK.DE has a market cap of 15.4M. Regarding current trading prices, ZOE.DE is priced at €102.18, while B8FK.DE trades at €2.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZOE.DE currently has a P/E ratio of 19.30, whereas B8FK.DE's P/E ratio is -7.06. In terms of profitability, ZOE.DE's ROE is +0.58%, compared to B8FK.DE's ROE of -0.02%. Regarding short-term risk, ZOE.DE is less volatile compared to B8FK.DE. This indicates potentially lower risk in terms of short-term price fluctuations for ZOE.DE.Check B8FK.DE's competition here
ZOE.DE vs SBX.DE Comparison April 2026
ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZOE.DE stands at 44.8B. In comparison, SBX.DE has a market cap of 9.6M. Regarding current trading prices, ZOE.DE is priced at €102.18, while SBX.DE trades at €1.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZOE.DE currently has a P/E ratio of 19.30, whereas SBX.DE's P/E ratio is -1.22. In terms of profitability, ZOE.DE's ROE is +0.58%, compared to SBX.DE's ROE of -0.55%. Regarding short-term risk, ZOE.DE is more volatile compared to SBX.DE. This indicates potentially higher risk in terms of short-term price fluctuations for ZOE.DE.Check SBX.DE's competition here
ZOE.DE vs Z6A.F Comparison April 2026
ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZOE.DE stands at 44.8B. In comparison, Z6A.F has a market cap of 4.5M. Regarding current trading prices, ZOE.DE is priced at €102.18, while Z6A.F trades at €0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZOE.DE currently has a P/E ratio of 19.30, whereas Z6A.F's P/E ratio is -0.02. In terms of profitability, ZOE.DE's ROE is +0.58%, compared to Z6A.F's ROE of -0.23%. Regarding short-term risk, ZOE.DE is more volatile compared to Z6A.F. This indicates potentially higher risk in terms of short-term price fluctuations for ZOE.DE.Check Z6A.F's competition here
ZOE.DE vs PA8.DE Comparison April 2026
ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZOE.DE stands at 44.8B. In comparison, PA8.DE has a market cap of 2.7M. Regarding current trading prices, ZOE.DE is priced at €102.18, while PA8.DE trades at €0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZOE.DE currently has a P/E ratio of 19.30, whereas PA8.DE's P/E ratio is -0.13. In terms of profitability, ZOE.DE's ROE is +0.58%, compared to PA8.DE's ROE of -0.09%. Regarding short-term risk, ZOE.DE is less volatile compared to PA8.DE. This indicates potentially lower risk in terms of short-term price fluctuations for ZOE.DE.Check PA8.DE's competition here
ZOE.DE vs 2NU.F Comparison April 2026
ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZOE.DE stands at 44.8B. In comparison, 2NU.F has a market cap of 1.1M. Regarding current trading prices, ZOE.DE is priced at €102.18, while 2NU.F trades at €0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZOE.DE currently has a P/E ratio of 19.30, whereas 2NU.F's P/E ratio is -0.03. In terms of profitability, ZOE.DE's ROE is +0.58%, compared to 2NU.F's ROE of N/A. Regarding short-term risk, ZOE.DE is less volatile compared to 2NU.F. This indicates potentially lower risk in terms of short-term price fluctuations for ZOE.DE.Check 2NU.F's competition here
ZOE.DE vs ERV2.F Comparison April 2026
ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZOE.DE stands at 44.8B. In comparison, ERV2.F has a market cap of 329.9K. Regarding current trading prices, ZOE.DE is priced at €102.18, while ERV2.F trades at €0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZOE.DE currently has a P/E ratio of 19.30, whereas ERV2.F's P/E ratio is -0.02. In terms of profitability, ZOE.DE's ROE is +0.58%, compared to ERV2.F's ROE of +2.97%. Regarding short-term risk, ZOE.DE is more volatile compared to ERV2.F. This indicates potentially higher risk in terms of short-term price fluctuations for ZOE.DE.Check ERV2.F's competition here
ZOE.DE vs PA8.F Comparison April 2026
ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZOE.DE stands at 44.8B. In comparison, PA8.F has a market cap of 259.7K. Regarding current trading prices, ZOE.DE is priced at €102.18, while PA8.F trades at €0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZOE.DE currently has a P/E ratio of 19.30, whereas PA8.F's P/E ratio is N/A. In terms of profitability, ZOE.DE's ROE is +0.58%, compared to PA8.F's ROE of +0.00%. Regarding short-term risk, ZOE.DE is more volatile compared to PA8.F. This indicates potentially higher risk in terms of short-term price fluctuations for ZOE.DE.Check PA8.F's competition here
ZOE.DE vs BIO1.F Comparison April 2026
ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZOE.DE stands at 44.8B. In comparison, BIO1.F has a market cap of 0. Regarding current trading prices, ZOE.DE is priced at €102.18, while BIO1.F trades at €36.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZOE.DE currently has a P/E ratio of 19.30, whereas BIO1.F's P/E ratio is -22.85. In terms of profitability, ZOE.DE's ROE is +0.58%, compared to BIO1.F's ROE of -0.08%. Regarding short-term risk, ZOE.DE is more volatile compared to BIO1.F. This indicates potentially higher risk in terms of short-term price fluctuations for ZOE.DE.Check BIO1.F's competition here
ZOE.DE vs 4XT.DE Comparison April 2026
ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZOE.DE stands at 44.8B. In comparison, 4XT.DE has a market cap of 0. Regarding current trading prices, ZOE.DE is priced at €102.18, while 4XT.DE trades at €0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZOE.DE currently has a P/E ratio of 19.30, whereas 4XT.DE's P/E ratio is -2.18. In terms of profitability, ZOE.DE's ROE is +0.58%, compared to 4XT.DE's ROE of -7.27%. Regarding short-term risk, ZOE.DE is more volatile compared to 4XT.DE. This indicates potentially higher risk in terms of short-term price fluctuations for ZOE.DE.Check 4XT.DE's competition here
ZOE.DE vs MCD.DE Comparison April 2026
ZOE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZOE.DE stands at 44.8B. In comparison, MCD.DE has a market cap of 0. Regarding current trading prices, ZOE.DE is priced at €102.18, while MCD.DE trades at €0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZOE.DE currently has a P/E ratio of 19.30, whereas MCD.DE's P/E ratio is -0.02. In terms of profitability, ZOE.DE's ROE is +0.58%, compared to MCD.DE's ROE of -1.69%. Regarding short-term risk, ZOE.DE is less volatile compared to MCD.DE. This indicates potentially lower risk in terms of short-term price fluctuations for ZOE.DE.Check MCD.DE's competition here